KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Current Assets (2016 - 2025)

Historic Current Assets for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Halozyme Therapeutics' Current Assets rose 1790.39% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 1790.39%. This contributed to the annual value of $1.1 billion for FY2024, which is 4540.53% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Current Assets of $1.3 billion as of Q3 2025, which was up 1790.39% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Current Assets ranged from a high of $1.3 billion in Q3 2025 and a low of $541.9 million during Q2 2022
  • Moreover, its 5-year median value for Current Assets was $941.7 million (2021), whereas its average is $926.4 million.
  • Its Current Assets has fluctuated over the past 5 years, first surged by 10391.04% in 2021, then tumbled by 4579.26% in 2022.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Current Assets stood at $926.3 million in 2021, then dropped by 20.22% to $739.0 million in 2022, then grew by 1.0% to $746.4 million in 2023, then soared by 45.41% to $1.1 billion in 2024, then increased by 22.43% to $1.3 billion in 2025.
  • Its Current Assets stands at $1.3 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $1.3 billion for Q1 2025.